Method for testing tertiary lymphoid tissue, and kit for testing tertiary lymphoid tissue

The method of using urine glutathione levels as a biomarker for TLT detection provides a non-invasive, safer approach to assess TLT presence and kidney health, addressing the invasive challenges of current tissue sampling methods and enabling early therapeutic interventions.

WO2024242058A1PCT designated stage expired Publication Date: 2024-11-28KYOTO UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/JP2024/018364
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-05-17
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Current methods for detecting tertiary lymphoid tissue (TLT) in patients, particularly those with kidney diseases or post-transplant patients, are invasive and burdensome, involving tissue sampling that carries risks, especially for patients on antiplatelet drugs or the elderly, and lack non-invasive alternatives.

Method used

A method and kit for testing the presence or absence of TLT by measuring glutathione concentration in urine samples, using glutathione as a biomarker, allowing for non-invasive assessment without the need for biological tissue diagnosis.

Benefits of technology

Enables the prediction of kidney damage and renal function decline, facilitating early therapeutic intervention by determining TLT presence and maturity levels through a non-invasive urine test, improving patient safety and reducing procedural burdens.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure JP2024018364_28112024_PF_FP_ABST
    Figure JP2024018364_28112024_PF_FP_ABST
Patent Text Reader

Abstract

One purpose of the present disclosure is to provide a technique for testing the presence or absence of a tertiary lymphoid tissue in a subject without conducting biopsy. The method for testing the presence or absence of a tertiary lymphoid tissue in a subject comprises a step for measuring the concentration of glutathione in a bodily fluid sample collected from the subject.
Need to check novelty before this filing date? Find Prior Art

Description

Method for testing tertiary lymphatic tissue and kit for testing tertiary lymphatic tissue

[0001] The present disclosure relates to a method for testing for the presence or absence of tertiary lymphoid tissue (TLT) in a subject, and to a kit for testing for the presence or absence of TLT in a subject.

[0002] TLTs are induced ectopic lymphoid tissues, which are tissues similar to lymph nodes that form in non-lymphoid tissues (Non-Patent Documents 1-3). TLTs are infiltrated with large numbers of lymphocytes, and serve as the origin of adaptive immune responses through the interaction and proliferation of T cells and B cells, amplifying the immune response. TLTs are known to form in lesions of diseases accompanied by chronic inflammation, autoimmune diseases, infectious diseases, cancer, etc. (Non-Patent Documents 1-3), and are known to affect the severity and prognosis of these diseases.

[0003] For example, in kidney diseases such as pyelonephritis, IgA nephropathy, and lupus nephritis, the induction of TLTs is known to lead to prolonged inflammation and repair failure (Non-Patent Document 4). Furthermore, the present inventors have recently demonstrated that TLT maturity can be used as a biomarker reflecting the degree of renal tissue injury (Non-Patent Document 5). Specifically, tissue analysis of human pyelonephritis has revealed that TLTs of various maturation stages simultaneously occur in the kidney. More mature TLTs are observed in areas with severe tissue injury, while in areas with mild injury, TLT induction is less pronounced and a higher proportion of immature TLTs are formed. Furthermore, analysis of elderly patients with chronic kidney disease has confirmed that the number of TLTs and the proportion of more mature TLTs are significantly higher in patients with chronic kidney disease than in patients without complications. Furthermore, it has been confirmed that TLTs are induced in the same anatomical location and through the same maturation stages, regardless of the type of underlying disease. It has also been reported that the presence of highly mature TLTs in transplanted kidneys is associated with a greater likelihood of a decline in renal function five years later (Non-patent Document 6), and TLTs are thought to be a potential predictive marker for future renal function.

[0004] Thus, TLTs are known to affect the severity of disease, prognosis, and response to treatment. Therefore, confirming the presence or absence of TLT formation and its maturity is useful for determining therapeutic intervention strategies and assessing their effectiveness.

[0005] On the other hand, to confirm the presence or absence of TLT formation, it is necessary to collect tissue from the lesion site and perform biopsy. However, collecting tissue from the lesion site requires maintaining a constant position for a certain period of time, and there is a risk of bleeding, which places a heavy burden on the patient. Furthermore, tissue collection is risky for patients undergoing treatment with antiplatelet drugs and elderly patients, making it particularly difficult to confirm the presence or absence of TLT formation in these patients.

[0006] Sato Y. et al., Immunology of the ageing kidney. Nat Rev Nephrol. 2019;15(10):625-40.Antonioli L. et al. Ectopic Lymphoid Organs and Immune-Mediated Diseases: Molecular Basis for Pharmacological Approaches. Trends Mol Med. 2020;26(11):1021-1033.Sautes-Fridman C. et al. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19(6):307-25.Sato Y. et al. Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney. JCI Insight. 2016;1(11):e87680.Sato Y. et al. Developmental stages of tertiary lymphoid tissue reflect local injury and inflammation in mouse and human kidneys. Kidney Int. 2020;98(2):448-463.Lee H. et al., HYPERLINK "https: / / pubmed.ncbi.nlm.nih.gov / 34725107 / "Advanced Tertiary Lymphoid Tissues in Protocol Biopsies are Associated with Progressive Graft Dysfunction in Kidney Transplant Recipients. J Am Soc Nephrol. 2022;33(1):186-200. doi: 10.1681 / ASN.2021050715.

[0007] One object of the present disclosure is to provide a technique for testing the presence or absence of TLTs in a subject without relying on biopsy.

[0008] The present inventors have conducted extensive research to solve the above-mentioned problems and have found that in mice in which TLT is formed in the kidney, glutathione accumulates in TLT and that the concentration of glutathione in urine samples is increased. Furthermore, the present inventors analyzed the concentration of glutathione in urine samples from IgA nephropathy patients, dividing them into groups based on the presence or absence of TLT. They found that the concentration of glutathione in urine samples from patients with TLT was significantly increased compared to patients without TLT. The present disclosure was completed through further research based on these findings.

[0009] That is, the present disclosure provides the following aspects of the invention. Item 1. A method for testing the presence or absence of TLT in a subject, comprising the step of measuring the glutathione concentration in a body fluid sample collected from the subject. Item 2. The testing method according to Item 1, wherein the body fluid sample is a urine sample. Item 3. The testing method according to Item 1 or 2, wherein the glutathione concentration is reduced glutathione concentration. Item 4. The testing method according to Item 2, further comprising the step of measuring the creatinine concentration in a urine sample. Item 5. The testing method according to any one of Items 1 to 4, wherein the subject is a kidney disease patient, a person in need of testing for the presence or absence of kidney disease, or a kidney transplant recipient, and the method is performed to test for the presence or absence of TLT in the kidney. Item 6. A test kit for testing the presence or absence of TLT in a living body, comprising a reagent for measuring glutathione concentration. Item 7. Use of a reagent for measuring glutathione concentration in the manufacture of a test kit for testing the presence or absence of TLT in a living body.

[0010] According to one embodiment of the testing method of the present disclosure, the presence or absence of TLT in a subject can be tested without relying on biopsy tissue diagnosis by using the glutathione concentration in a body fluid sample such as urine as a TLT biomarker. Furthermore, for example, by using the testing method of the present disclosure to predict the presence or absence of TLT in the kidneys of a kidney disease patient or a kidney transplant recipient, the degree of renal damage and the function of the transplanted kidney can be estimated, enabling early therapeutic intervention for patients at high risk of deterioration of transplanted kidney function.

[0011] Schematic diagrams of the structure of TLTs formed in the kidney at various stages of maturity are shown. (a) Experimental scheme for measuring glutathione levels in kidney tissue and urine in a renal TLT model created by inducing ischemia-reperfusion injury (IRI). (b) Images of kidney tissue from IRI-induced mice, stained with HE (left) and immunostained with anti-CD3e and anti-B220 antibodies (right). (c) Images of kidney tissue from IRI-induced and control mice, including HE-stained image (leftmost), mass spectrometry (MSI) image of oxidized glutathione (GSSG) (second from the left), MSI image of reduced glutathione (GSH) (second from the right), and a merged image of HE-stained and GSSG MSI images (rightmost). In the HE-stained image (c), the arrow indicates the formation of TLTs. Figure 3(d) shows a magnified HE-stained image (left), a GSSG MSI image (middle), and a GSH MSI image (right) of the region where TLTp was formed in the kidney tissue of an IRI-induced mouse. The lower image (high) in figure 3(d) is a further magnified image of the region enclosed by the dotted line in the upper image (low). Figure 3(e) shows the results of measuring the relative amounts of GSH, GSSG, cystine, cysteine, the dipeptide Cys-Gly, and γ-glutamylcysteine ​​extracted from the kidney tissue of an IRI-induced mouse and a control mouse. In figure 3(e), * indicates p < 0.05. The relative urinary reduced glutathione concentrations (relative to the urinary creatinine concentration of 1) of an IRI-induced mouse and a control mouse are shown. In figure 3(d), * indicates p < 0.05, and ns indicates no significant difference. The figure shows the results of dividing IgA nephropathy patients into a TLT-containing group (TLT+) and a TLT-free group (TLT-) and determining the relative urinary reduced glutathione concentration (relative value with urinary creatinine concentration set to 1). The figure shows the results of logistic regression analysis and ROC analysis of IgA nephropathy patients, where patients in the TLT-containing group were defined as positive (1) and patients in the TLT-free group as negative (0), and the relative urinary reduced glutathione concentration (relative value with urinary creatinine concentration set to 1) was used as an explanatory variable.

[0012] 1. Terms Unless otherwise specified, terms used herein have the meanings that are commonly understood by those skilled in the art of medicine, pharmacology, molecular biology, microbiology, organic chemistry, etc. If a term defined herein does not have the same meaning as commonly understood, the description in this specification shall take precedence.

[0013] In this disclosure, "tertiary lymphoid tissues (TLTs)" are tissues similar to lymph nodes, composed of lymphocyte aggregates, and are inducible ectopic lymphoid tissues formed in non-lymphoid tissues. In this disclosure, "maturity of tertiary lymphoid tissues (TLTs)" refers to the degree of structural maturity of TLTs. In this disclosure, the maturity of tertiary lymphoid tissues (TLTs) is classified into stages I to III as follows, in accordance with the classification described in Non-Patent Document 5. For reference, Figure 1 shows structural diagrams of TLTs formed in the kidney at each maturity stage. Stage 0 in Figure 1 is a stage in which lymphocytes are not organized and are precursors of TLTs, and does not correspond to the TLTs defined in this disclosure. Stage I: TLTs that do not contain follicular dendritic cells (FDCs) or germinal centers. Stage II: TLTs that contain FDCs but not germinal centers. Stage III: TLTs that contain FDCs and germinal centers.

[0014] In the present disclosure, the term "glutathione" is a concept that includes both reduced glutathione and oxidized glutathione. Reduced glutathione is a tripeptide in which glutamic acid, cysteine, and glycine are peptide-bonded in this order. However, in reduced glutathione, glutamic acid and cysteine ​​are bonded by an amide bond between the γ-carboxyl group of the side chain of glutamic acid and the amino group of cysteine. Oxidized glutathione is a molecule in which two molecules of reduced glutathione are linked by a disulfide bond.

[0015] 2. TLT Testing Method The testing method of the present disclosure is a method for testing the presence or absence of TLT in a subject, and includes a step of measuring the glutathione concentration in a body fluid sample collected from the subject. The testing method of the present disclosure is described in detail below.

[0016] [Subject] In the testing method of the present disclosure, a "subject" refers to a human or non-human animal that is the subject of testing for the presence or absence of TLT formation in vivo. Examples of non-human animals include non-human mammals such as primates, rats, mice, gerbils, guinea pigs, hamsters, ferrets, rabbits, cows, horses, pigs, goats, dogs, and cats. A preferred example of a subject is a human.

[0017] The subject in the testing method of the present disclosure may be any person for whom testing for the presence or absence of TLT formation in vivo is required, and suitable examples include individuals suffering from a disease in which TLT formation occurs in the lesions, individuals who need testing for the presence or absence of such a disease, and individuals who have undergone organ transplants for the treatment of such a disease. Examples of diseases in which TLT formation occurs in the lesions include diseases accompanied by chronic inflammation, chronic kidney disease, obesity, asthma, allergic lung disease, arteriosclerosis, autoimmune diseases, infectious diseases, and cancer.

[0018] Specific examples of subjects in the testing method of the present disclosure include kidney disease patients and those who need to be tested for kidney disease. The type of kidney disease is not particularly limited, and examples include IgA nephropathy, lupus nephritis, ANCA-associated vasculitis, diabetic nephropathy, nephrosclerosis, pyelonephritis, and chronic renal failure. Among these kidney diseases, IgA nephropathy is preferred. In kidney disease, as renal dysfunction progresses, TLTs tend to form more easily in the affected area and their maturity tends to increase. Therefore, in the testing method of the present disclosure, when a subject is a person suffering from kidney disease or a person who needs to be tested for kidney disease, the presence or absence of kidney disease can be inferred in addition to the presence or absence of TLTs.

[0019] Another specific example of a subject in the testing method of the present disclosure is a person who needs to have their future renal function predicted. Examples of people who need to have their future renal function predicted include kidney disease patients and people who have received kidney transplants. For example, when a person who has received a kidney transplant is used as a subject, the prognosis of transplanted kidney function can be predicted depending on the presence or absence of TLT.

[0020] Further, other specific examples of subjects in the testing method of the present disclosure include hepatitis C patients and people who need to be tested for the presence or absence of hepatitis C. As the symptoms of hepatitis C progress, TLTs tend to be more easily formed in the liver and their maturity tends to increase. Therefore, when a person who has hepatitis C or who needs to be tested for the presence or absence of hepatitis C is used as a subject in the testing method of the present disclosure, in addition to the presence or absence of TLTs, the presence or absence of hepatitis C and the severity of the symptoms of hepatitis C can be inferred.

[0021] Another specific example of a subject in the testing method of the present disclosure is a cancer patient. The type of cancer is not particularly limited, and examples include solid cancers such as kidney cancer, stomach cancer, lung cancer, breast cancer, liver cancer, tongue cancer, thyroid cancer, uterine cancer, ovarian cancer, and prostate cancer. When TLTs are formed in cancer tissue and their maturity increases, the cancer immune response improves, and there is a tendency for improved cancer treatment efficacy and a good prognosis to be observed. Therefore, when cancer patients, particularly cancer patients administered with immune checkpoint inhibitors, are used as subjects in the testing method of the present disclosure, the cancer treatment efficacy and prognosis can be predicted.

[0022] [Body fluid sample] A "body fluid sample" refers to a body fluid such as urine, saliva, blood, sputum, or sweat collected from the subject, or a sample prepared from the body fluid. Among these body fluid samples, urine is preferred because it can be used to test for the presence or absence of TLT with high accuracy and can be collected non-invasively. Furthermore, the body fluid sample may be concentrated, filtered, or the like, as necessary.

[0023] [Measurement of Glutathione Concentration] In the testing method of the present disclosure, the glutathione concentration in a body fluid sample is measured, since the glutathione concentration in the body fluid sample is used as a biomarker for TLT.

[0024] The glutathione to be measured may be reduced glutathione, oxidized glutathione, or total glutathione (both reduced glutathione and oxidized glutathione).

[0025] The glutathione concentration in a body fluid sample can be measured by a known method. For example, kits capable of quantifying glutathione concentration are commercially available, and the glutathione concentration in a body fluid sample can be measured using a commercially available kit. Alternatively, the glutathione concentration in a body fluid sample can be measured using an ion chromatography-Fourier transform mass spectrometer (IC-FTMS), a liquid chromatography-tandem mass spectrometer (LC-MS / MS), or the like.

[0026] Furthermore, when a urine sample is used as the body fluid sample, the urinary glutathione concentration may vary depending on the urine volume, and therefore it is desirable to correct the urinary glutathione concentration based on the urinary creatinine concentration, etc. For example, in one embodiment of the testing method of the present disclosure in which a urine sample is used as the body fluid sample, the value obtained by dividing the urinary glutathione concentration by the urinary creatinine concentration (creatinine-corrected value) is used as an index of the urinary glutathione concentration.

[0027] [Determination of the Presence or Absence of TLT] The testing method of the present disclosure can be applied to testing for the presence or absence of TLT in any lesion site, but a suitable example is application to testing for the presence or absence of TLT in the kidney.

[0028] There is a correlation between the presence or absence of TLT and the glutathione concentration in a body fluid sample: if TLT is not formed in vivo, the glutathione concentration in the body fluid sample is low, and if TLT is formed in vivo, the glutathione concentration in the body fluid sample is high. Therefore, in the testing method of the present disclosure, it is determined that the lower the glutathione concentration in a body fluid sample, the higher the possibility that TLT is not formed in vivo, and the higher the glutathione concentration in a body fluid sample, the higher the possibility that TLT is formed in vivo.

[0029] The testing method of the present disclosure allows the determination of the presence or absence of TLT based on the glutathione concentration in a body fluid sample to be made by comparing it with a reference value previously determined from individuals whose TLT status is known. Here, the "reference value" refers to a standard value for determining the presence or absence of TLT, specifically, the average glutathione concentration in body fluid samples determined from individuals whose TLT status is known, a cutoff value determined from the glutathione concentration in the body fluid sample, etc.

[0030] For example, the average glutathione concentration in body fluid samples from individuals who do not form TLT in vivo is determined in advance and used as a reference value, and if the glutathione concentration in the subject's body fluid sample is equal to or lower than the reference value, it can be determined that the subject is likely to not form TLT in vivo.Alternatively, the average glutathione concentration in body fluid samples from individuals who form TLT in vivo is determined in advance and used as a reference value, and if the glutathione concentration in the subject's body fluid sample is equal to or higher than the reference value, it can be determined that the subject is likely to form TLT in vivo. Furthermore, for example, the average glutathione concentration in body fluid samples from individuals in whom TLT is not formed in vivo and the average glutathione concentration in body fluid samples from individuals in whom TLT is formed in vivo are determined in advance, and a cutoff value for distinguishing the presence or absence of TLT from these glutathione concentrations is determined.The cutoff value is used as a reference value, and if the glutathione concentration in the subject's body fluid sample is equal to or higher than the cutoff value, it can be determined that the subject is likely to form TLT in vivo.

[0031] It is desirable to determine the reference value for each type of disease to be tested. For example, if the subject is a kidney disease patient or a person who needs to be tested for kidney disease, the reference value may be the average glutathione concentration in body fluid samples from kidney disease patients who are known not to form TLT in their kidneys, the glutathione concentration in blood and body fluid samples from kidney disease patients who are known to form TLT in their kidneys, and / or a cutoff value determined from these glutathione concentrations. Furthermore, for example, if the subject is a hepatitis C patient or a person who needs to be tested for hepatitis C, the reference value may be the average glutathione concentration in body fluid samples from hepatitis C patients who are known not to form TLT in their livers, the average glutathione concentration in body fluid samples from hepatitis C patients who are known to form TLT in their livers, and / or a cutoff value determined from these glutathione concentrations.

[0032] Furthermore, as shown in the Examples section, analysis of 47 patients with IgA nephropathy grouped according to the presence or absence of TLT formation in the kidneys confirmed that the mean relative urinary glutathione concentration (relative urinary glutathione concentration when the urinary creatinine concentration is set to 1) for the patient group with TLT formation in the kidney was 0.000740, while the mean relative urinary glutathione concentration for the patient group without TLT formation in the kidney was 0.000169. The cutoff value for the relative urinary glutathione concentration, which can distinguish these two groups with a sensitivity of 0.7143 and a specificity of 1 minus 0.00556, was 0.0001647. Therefore, when the testing method of the present disclosure is applied to testing the presence or absence of TLT in the kidney using a urine sample as the body fluid sample, these mean or cutoff values ​​of urinary glutathione concentrations can also be used as reference values.

[0033] Based on the presence or absence of TLT in a living body predicted by the testing method of the present disclosure, it is possible to infer the presence or absence of a disease in which TLT formation occurs in the lesion, or the severity of the symptoms of the disease.

[0034] For example, if the subject suffers from a disease other than cancer accompanied by TLT formation and it is predicted that TLT may be formed in vivo in the test method of the present disclosure, it is presumed that the disease is progressing. Specifically, if the subject is a kidney disease patient and it is predicted that TLT may be formed in vivo in the test method of the present disclosure, it is presumed that the kidney disease is progressing.

[0035] Furthermore, therapeutic drugs targeting TLT may be effective for diseases accompanied by TLT formation (other than those associated with cancer and infection), and the development of therapeutic drugs targeting TLT is expected in the future. Therefore, the testing method disclosed herein can also be used to determine whether or not to administer therapeutic drugs targeting TLT that may be developed in the future. Specifically, in the testing method disclosed herein, if a subject is a patient suffering from a disease accompanied by TLT formation other than those associated with cancer and infection and it is predicted that TLT may be formed in vivo, it can be determined that the patient is suitable for administration of a therapeutic drug targeting TLT. In addition, in the present disclosure, a "therapeutic drug targeting TLT" refers to a drug that stops or suppresses the progression of TLT, or causes the disappearance or reduction of TLT.

[0036] Furthermore, in the testing method of the present disclosure, even if a subject needs to have their future renal function predicted and their renal function is normal at the time of testing, if it is predicted that TLTs may be formed, it is inferred that there is a possibility of a decline in renal function in the future. For example, even if a subject is a kidney transplant recipient and the function of the transplanted kidney is normal at the time of testing, if it is predicted that TLTs may be formed, it is inferred that there is a possibility of a worsening prognosis for transplanted kidney function.

[0037] Furthermore, in the testing method of the present disclosure, if the subject is a cancer patient and it is predicted that TLTs may be formed in vivo, it is presumed that the cancer immune response is improved.

[0038] 3. TLT Test Kit Another embodiment of the present disclosure provides a kit for testing for the presence or absence of TLT in a living body, which includes a reagent for measuring glutathione concentration. The test kit of the present disclosure is a test kit used to carry out the test method, and the contents described in the section "2. TLT Test Method" above are also incorporated by reference into the test kit of the present disclosure. The test kit of the present disclosure can also be provided as an in vitro diagnostic reagent for testing for the presence or absence of TLT in a living body.

[0039] The test kit of the present disclosure may include any reagent for measuring glutathione concentration, such as an enzyme, coenzyme, buffer, substrate, internal standard, etc. One example of a reagent for measuring glutathione concentration is a combination of glutathione reductase, NADPH, and DTNB (5-5'-dithiobis[2-nitrobenzoic acid]). Another example of a reagent for measuring glutathione concentration is a combination of glutathione S-transferase, luciferin-NT (Promega), and luciferase.

[0040] When measuring the glutathione concentration in a urine sample using the test kit of the present disclosure, the test kit of the present disclosure may include a reagent for measuring the creatinine concentration in order to correct the glutathione concentration in the urine sample. The reagent for measuring the creatinine concentration may include, for example, an enzyme for detecting creatinine by enzymatic measurement, specifically, creatininase, creatinase, sarcosine oxidase, and a detection agent for reactive oxygen species (e.g., peroxidase, 4-aminoantipyrine, and N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine).

[0041] The present disclosure is not limited in any way to the above-described embodiments of the invention or the following examples. Various modifications within the scope of the claims and within the scope that can be easily conceived by a person skilled in the art are also included in the present invention. The contents of the literature and other documents cited in this specification are incorporated herein by reference in their entirety.

[0042] 1. Analysis using the kidney TLT model 1-1. Test materials and methods (1) Mice Twelve-month-old C57BL6J mice were purchased from Japan SCL Co., Ltd. All mice were kept in an SPF (specific pathogen-free) environment at the Kyoto University Animal Experiment Facility. All animal experiments were approved by the Kyoto University Animal Experiment Committee and conducted in accordance with the US National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals.

[0043] (2) Renal TLT Model: Mice were anesthetized with 2% isoflurane, and a skin incision was made to expose the left kidney. Ischemia-reperfusion injury (IRI) was induced by completely occluding both renal arteries using vascular clamps for 45 minutes, followed by release and closure. Urine was collected weekly from the day of IRI induction. Mice were sacrificed 45 days after IRI induction, and kidney tissue was collected (n = 5). Urine and kidney tissue were also collected under the same conditions as above, except that IRI induction was not performed (control) (n = 5).

[0044] (3) Renal tissue staining (HE staining and immunostaining) Hematoxylin-eosin (HE) staining of kidney tissue was performed as follows. Immediately after sacrifice, kidney tissue was flash-frozen on dry ice and sliced ​​unembedded at 8 μm using a cryostat (CM3050, Leica). The sliced ​​tissue was fixed on glass slides (Matsunami Glass Ind.) and infiltrated in hematoxylin staining solution for 4 minutes. It was then washed in running water for 15 minutes, infiltrated in eosin staining solution for 2 minutes, and then subjected to HE staining.

[0045] Renal tissue immunostaining was performed as follows. First, kidney tissue sections were blocked with phosphate-buffered saline (PBS) containing 5% normal goat serum for 1 hour at room temperature. Then, the sections were incubated overnight at 4°C with primary antibodies: anti-B220 antibody (557390, BD Bioscience) and anti-CD3e antibody (55027, BD Bioscience). The appropriate secondary antibodies were then incubated for 1 hour at room temperature, followed by counterstaining with DAPI (4',6-diamidino-2-phenylindole). Observations were performed using a confocal microscope (FV1000D; Olympus Corporation).

[0046] (4) Renal Tissue Mass Imaging: Immediately after sacrifice, kidney tissue was flash-frozen on dry ice and sliced ​​unembedded at 8 μm using a cryostat (CM3050, Leica). The sliced ​​tissue was mounted on indium tin oxide (ITO)-coated glass slides (Brucker Daltonics). Matrix-assisted laser desorption / ionization mass spectrometry (MALDI-IMS) was performed using 9-aminoacridine (10 mg / mL, dissolved in 80% ethanol) as the matrix. MALDI imaging was performed using a matrix-assisted laser desorption / ionization time-of-flight (MALDI-TOF) mass spectrometer (UltraFlextreme, Brucker Daltonics) equipped with a Nd:YAG laser. Data were collected in negative reflection mode, with raster scans every 50 mm. Image reconstruction was performed using FlexImaging 4.1 software (Brucker Daltonics).

[0047] (5) Renal Tissue Metabolomic Analysis: Tissue sections embedded in Super Cryoembedding Medium (SCEM) were dissolved in 500 μL of methanol using a homogenizer (Finger Masher, AM79330, Sarstedt, Tokyo, Japan). An equal volume of chloroform and 0.4 volumes of ultrapure water were then added and mixed. The mixture was centrifuged at 15,000 x g for 15 minutes at 4°C. The resulting supernatant was filtered using an ultrafilter tube (Ultrafree-MC, UFC3 LCC NB; Human Metabolome Technologies, Tsuruoka, Japan). The filtrate was concentrated using a centrifugal concentrator (SpeedVac; Thermo, Yokohama, Japan). The concentrated filtrate was dissolved in 50 μL of ultrapure water and subjected to metabolomic analysis using a mass spectrometer. Metabolomic analysis was performed by separating anionic and cationic metabolites using the following method. For data analysis, the results for cationic metabolites, for which more precise values ​​are required, were used.

[0048] For metabolomic analysis of anionic metabolites, we used an ion chromatograph (IC)-Fourier transform mass spectrometer (FTMS). Specifically, anionic metabolites were measured using an orbitrap mass spectrometer (Q-Exactive focus, Thermo Fisher Scientific) connected to a high-performance IC system (ICS-5000+, Thermo Fisher Scientific). Highly selective and sensitive metabolite quantification was achieved using IC separation and Fourier transform mass spectrometry. The ion chromatograph was equipped with an anion electrolytic suppressor (Thermo Scientific Dionex AERS 500), and the potassium hydroxide gradient was converted to pure water before entering the mass spectrometer. Separation was performed using a Dionex TM IonPac TMThe analysis was performed using an AS11-HC-4 μm IC column (Thermo Scientific). The IC flow rate was 0.25 mL / min, with a post-column makeup flow of 0.18 mL / min supplemented with methanol. The potassium hydroxide gradient conditions for IC separation were as follows: 1 mM to 100 mM (0–40 min), 100 mM (40–50 min), and 1 mM (50.1–60 min). The column temperature was 30°C. The Orbitrap mass spectrometer was operated in negative ESI mode for all detections. Full mass scans (m / z 70–900) were performed at a resolution of 70,000. The automatic gain control (AGC) target was set to 3 × 106 ions, and the maximum ion injection time was set to 100 ms. The ion source ionization parameters were: spray voltage 3 kV, transfer temperature 320°C, S-Lens level 50, heater temperature 300°C, sheath gas 36, and auxiliary gas 10.

[0049] For metabolomic analysis of cationic metabolites, liquid chromatography-tandem mass spectrometry (LC-MS / MS) was used. Specifically, a triple quadrupole mass spectrometer (LCMS-8060, Shimadzu) equipped with an orthogonal electrospray (ESI) ion source was used in positive and negative ESI, multiple reaction monitoring (MRM) mode. Samples were separated on a Discovery HS F5-3 column (2.1 mm ID × 150 mm L, 3-μm particles, Sigma-Aldrich) using a step gradient of mobile phase A (0.1% formic acid) and mobile phase B (0.1% acetonitrile). A step gradient was performed with mobile phase A and mobile phase B in ratios of 100:0 (0-5 min), 75:25 (5-11 min), 65:35 (11-15 min), 5:95 (15-20 min), and 100:0 (20-25 min), at a flow rate of 0.25 mL / min and a column temperature of 40°C.

[0050] (6) Urinary Metabolomic Analysis. 50 μL of frozen urine was mixed with 500 μL of methanol and a standard (2-morpholinoethanesulfonic acid), followed by the addition of an equal volume of chloroform and 0.4 volumes of ultrapure water (LC / MS grade, FUJIFILM Wako). The resulting suspension was centrifuged at 2,800 g for 15 minutes at 4°C. After centrifugation, the aqueous phase was ultrafiltered using an ultrafiltration tube (Ultrafree MC-PLHCC; Human Metabolome Technologies). The filtrate was concentrated using a vacuum concentrator (SpeedVac, Thermo Fisher Scientific). The concentrated filtrate was dissolved in 50 μL of ultrapure water and analyzed by IC-FTMS and LC-MS / MS. To correct for the loss of endogenous metabolites during sample preparation, urinary metabolite concentrations were calculated as relative values ​​corrected for urinary creatinine concentration (creatinine concentration = 1). Analysis by IC-FTMS and LC-MS / MS was performed in the same manner as in the kidney tissue metabolome analysis.

[0051] 1-2. Results HE staining of kidney tissue from mice with ischemia-reperfusion injury revealed tissues that were suspected to be TLTs (Fig. 2b). Furthermore, the T cell marker CD3e and the B cell marker B220 were localized in the tissues suspected to be TLTs by HE staining (Fig. 2b), confirming that the TLTs were composed of aggregates of T cells and B cells.

[0052] Mass imaging of renal tissue from mice with ischemia-reperfusion injury confirmed that glutathione (oxidized and reduced forms) accumulated in TLTs (Fig. 2c, d). Furthermore, the amounts of glutathione (oxidized and reduced forms) and its degradation product (a dipeptide consisting of Cys-Gly) extracted from the kidneys of mice with ischemia-reperfusion injury were significantly increased compared to control mice (Fig. 2e).

[0053] Furthermore, the urinary reduced glutathione concentration was significantly increased in mice with ischemia-reperfusion injury compared with control mice (Fig. 3).

[0054] These results demonstrate that glutathione is highly accumulated in TLTs formed in the kidney, and that increased urinary glutathione concentrations are observed when TLTs are formed.

[0055] 2. Analysis using urine samples from patients with IgA nephropathy 2-1. Test materials and methods (1) Patients Forty-six patients with IgA nephropathy diagnosed by renal biopsy at Kyoto University Hospital between 2014 and 2018 were retrospectively screened. Of the 46 patients, 46 with remaining renal biopsy tissue and urine samples (frozen urine) and who had given consent for this study were included in the analysis. Note that patients who had received immunosuppressive therapy within one year prior to the renal biopsy, patients with systemic lupus erythematosus (SLE), patients with rheumatoid arthritis, patients with purpura nephritis, and patients with liver cirrhosis were excluded from the analysis.

[0056] (2) Identification of TLTs. In this study, TLTs were defined as organized lymphocyte aggregations with signs of proliferation, similar to the criteria set forth in Non-Patent Document 4. Because TLTs varied in size, in this study, TLTs were defined as aggregations of 61 or more lymphocytes (T cells and B cells) containing at least one Ki67-positive cell. Quantification of TLT numbers and staging were performed in a blinded manner according to the method described in Non-Patent Document 5. Briefly, mononuclear cell infiltration in the renal interstitium was first confirmed using PAS-stained sections. Next, mononuclear cell infiltration was assessed in two consecutive sections by immunofluorescent staining for 1) CD3ε and CD20, and 2) Ki67 and CD21, to diagnose TLTs. After the diagnosis of TLT, the stage of TLT was classified according to the following criteria: i) TLT without follicular dendritic cells (FDCs) or germinal centers (stage I), ii) TLT containing FDCs but lacking germinal centers (stage II), and iii) TLT containing both FDCs and germinal centers (stage III). FDCs were defined as cells strongly expressing CD21 within TLTs. Germinal centers were defined as microstructures containing clusters of 16 or more Ki67-positive cells within the B cell area.

[0057] Of the 46 patients with IgA nephropathy analyzed, TLT was observed in 18 cases and not in 28. When the TLT stage was determined for the 18 cases in which TLT was observed, 14 cases were stage I, 4 cases were stage II, and 0 cases were stage III.

[0058] (3) Urinary Metabolome Analysis The urinary reduced glutathione concentration was measured using the same method as described above in "1. Analysis using the kidney TLT model."

[0059] (4) Logistic regression analysis and receiver-operating characteristic (ROC) analysis were performed using JMP Pro software (version 16). Logistic regression was performed using oxidized glutathione as an explanatory variable to predict the presence or absence of TLT. Using the ROC curve and Youden index, the cutoff value of urinary oxidized glutathione concentration for predicting the presence of TLT was determined, and values ​​above the cutoff value were considered TLT-positive.

[0060] 2-2. Results Patients with IgA nephropathy were divided into a group with TLT and a group without TLT, and urinary reduced glutathione concentrations were measured. The mean relative value of urinary oxidized glutathione concentrations in the group with TLT was 0.000740, while the mean relative value of urinary oxidized glutathione concentrations in the group without TLT was 0.000169. The group with TLT had significantly increased urinary reduced glutathione concentrations compared to the group without TLT (Figure 4).

[0061] Univariate analysis was performed using logistic regression with the relative urinary reduced glutathione concentration as the explanatory variable, with patients in the TLT group defined as positive (1) and patients in the TLT-free group defined as negative (0). The results showed that the AUC (area under the curve) was 0.893, and the relative value of urinary reduced glutathione concentration at which the sensitivity minus (1 - specificity) was maximized was 0.0001647 (Figure 5). When this relative value was used as the cutoff value, the sensitivity was 0.7143 and the 1 - specificity was 0.0556 (Figure 5).

[0062] These results demonstrate that urinary glutathione concentrations are significantly increased in IgA nephropathy patients with TLT, and that the presence or absence of TLT can be predicted using urinary glutathione concentrations as an indicator.

Claims

1. A method for testing the presence or absence of tertiary lymphoid tissue in a subject, comprising the step of measuring the glutathione concentration in a body fluid sample taken from the subject.

2. The testing method according to claim 1, wherein the body fluid sample is a urine sample.

3. The testing method according to claim 1 or 2, wherein the glutathione concentration is reduced glutathione concentration.

4. The method according to claim 2, further comprising the step of measuring the creatinine concentration in a urine sample.

5. The method of testing according to claim 1 or 2, wherein the subject is a kidney disease patient, a person who needs to be tested for the presence or absence of kidney disease, or a person who has undergone a kidney transplant, and the method is performed to test for the presence or absence of tertiary lymphoid tissue in the kidney.

6. A test kit for detecting the presence or absence of tertiary lymphoid tissue in a living body, comprising a reagent for measuring glutathione concentration.

7. Use of a reagent for measuring glutathione concentration for the manufacture of a test kit for testing the presence or absence of tertiary lymphoid tissue in the body.

Citation Information

Patent Citations

  • Protein chip for detecting kidney injury marker and preparation method of protein chip

    CN111007255A

  • CXCL13 Marker For Predicting Immunotherapeutic Responsiveness In Patient With Lung Cancer And Use Thereof

    US20210363593A1

  • Method for testing tertiary lymphoid tissue, and kit for testing tertiary lymphoid tissue

    WO2023234422A1